CLN 619
Alternative Names: Anti-MICA/MICB monoclonal antibody; CLN-619Latest Information Update: 10 Jul 2024
At a glance
- Originator PDI Therapeutics
- Developer Cullinan Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Multiple myeloma
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 23 May 2024 Updated efficacy and adverse events data from a phase-I trial in Solid tumours released by Cullinan Oncology
- 24 Apr 2024 Cullinan Therapeutics plans a phase I trial for Multiple Myeloma(Second-line therapy or greater) (Parenteral) in September 2024 (NCT06381141)